BRPI0510119A - formulação para dpi contendo sulfoaquil éter de ciclodextrina - Google Patents

formulação para dpi contendo sulfoaquil éter de ciclodextrina

Info

Publication number
BRPI0510119A
BRPI0510119A BRPI0510119-0A BRPI0510119A BRPI0510119A BR PI0510119 A BRPI0510119 A BR PI0510119A BR PI0510119 A BRPI0510119 A BR PI0510119A BR PI0510119 A BRPI0510119 A BR PI0510119A
Authority
BR
Brazil
Prior art keywords
sae
dpi
formulation
vehicle
active agent
Prior art date
Application number
BRPI0510119-0A
Other languages
English (en)
Inventor
James D Pipkin
Rupert O Zimmerer
Anthony J Hickey
Diane O Thompson
Hugh D C Smyth
Original Assignee
Cydex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cydex Inc filed Critical Cydex Inc
Publication of BRPI0510119A publication Critical patent/BRPI0510119A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Abstract

FORMULAçãO PARA DPI CONTENDO SULFOALQUIL éTER DE CICLODEXTRINA. A presente invenção refere-se a uma formulação inalável em pó seco contendo SAE-CD e um agente ativo que é proporcionada. A formulação é adaptada para administração através de um DPI. O SAE-CD serve como um veículo ao invés de como um intensificador de absorção. O tamanho médio de partícula do SAE-CD é grande o bastante para evitar (pelo menos na maioria) depósito pulmonar do mesmo. Após liberação do dispositivo DPI, as partículas contendo SAE-CD se dissociam das partículas contendo agente ativo na cavidade bucal ou garganta, após o que as partículas contendo agente ativo permanecem mais profundas no trato respiratório. As propriedades físico-químicas e morfológicas do SAE-CD são facilmente modificadas para permitir otimização das interações de agente ativo e veículo. Fármacos tendo uma carga eletrostática positiva, neutra ou negativa podem ser distribuídos através do DPI quando SAE-CD é usado como um veículo.
BRPI0510119-0A 2004-04-23 2005-04-22 formulação para dpi contendo sulfoaquil éter de ciclodextrina BRPI0510119A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56489204P 2004-04-23 2004-04-23
PCT/US2005/014010 WO2005104712A2 (en) 2004-04-23 2005-04-22 Dpi formulation containing sulfoalkyl ether cyclodextrin

Publications (1)

Publication Number Publication Date
BRPI0510119A true BRPI0510119A (pt) 2007-09-25

Family

ID=35242136

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510119-0A BRPI0510119A (pt) 2004-04-23 2005-04-22 formulação para dpi contendo sulfoaquil éter de ciclodextrina

Country Status (19)

Country Link
US (4) US8114438B2 (pt)
EP (3) EP2708225B1 (pt)
JP (4) JP2007534693A (pt)
KR (3) KR20120089705A (pt)
CN (1) CN101098678A (pt)
AU (2) AU2005237523A1 (pt)
BR (1) BRPI0510119A (pt)
CA (1) CA2562585A1 (pt)
DK (2) DK2708225T3 (pt)
ES (2) ES2909080T3 (pt)
HU (2) HUE042304T2 (pt)
IL (1) IL178728A0 (pt)
LT (1) LT2708225T (pt)
MX (1) MXPA06012240A (pt)
PL (1) PL2708225T3 (pt)
PT (2) PT2708225T (pt)
RU (1) RU2006141358A (pt)
SI (1) SI2708225T1 (pt)
WO (1) WO2005104712A2 (pt)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004073729A1 (ja) 2003-02-21 2004-09-02 Translational Research Ltd. 薬物の経鼻投与用組成物
MXPA05010379A (es) 2003-03-27 2006-05-31 Bioactis Ltd Aparato para administrar una medicina en polvo en la cavidad intranasal.
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20070020298A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
HUE042304T2 (hu) 2004-04-23 2019-06-28 Cydex Pharmaceuticals Inc DPI készítmény, amely szulfoalkil-éter-ciklodextrint tartalmaz
EP1785145A4 (en) 2004-08-10 2008-08-13 Translational Res Ltd TRANSNASAL COMPOSITION WITH IMMEDIATE EFFECT AND HIGH RESORBIBILITY
DE602005027415D1 (de) * 2005-10-26 2011-05-19 Cydex Pharmaceuticals Inc Sulfoalkylether-cyclodextrin-zusammensetzungen und herstellungsverfahren dafür
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
US20070111965A1 (en) * 2005-11-15 2007-05-17 Kipp James E Compositions comprising lipoxygenase inhibitors and cyclodextrin
EP2116264B1 (en) 2006-12-26 2017-09-27 Shin Nippon Biomedical Laboratories, Ltd. Preparation for transnasal application
GB2448183A (en) * 2007-04-05 2008-10-08 Optinose As Nasal powder delivery device
GB0712316D0 (en) * 2007-06-26 2007-08-01 Entripneur Ltd A novel powder and its method of manufacture
WO2009061273A1 (en) * 2007-11-07 2009-05-14 Astrazeneca Ab Dry powder formulations comprising ascorbic acid derivates
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
WO2010014827A2 (en) 2008-07-30 2010-02-04 Stc.Unm Formulations containing large-size carrier particles for dry powder inhalation aerosols
US20100034967A1 (en) * 2008-08-07 2010-02-11 Vector Corporation Dry polymer layering using a rotor processor
US20100034968A1 (en) * 2008-08-07 2010-02-11 Vector Corporation Polymer coating process using dry glidant in a rotor processor
US8807070B2 (en) * 2008-08-07 2014-08-19 Vector Corporation Rotor processor for dry powders
TWI478915B (zh) 2008-10-27 2015-04-01 Cellceutix Corp 宿主防禦之合成模擬物及其用途
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US9101539B2 (en) 2009-05-15 2015-08-11 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
US8492538B1 (en) 2009-06-04 2013-07-23 Jose R. Matos Cyclodextrin derivative salts
GB2472327B (en) 2009-07-31 2013-03-13 Shin Nippon Biomedical Lab Ltd Intranasal granisetron and nasal applicator
WO2011131663A1 (en) 2010-04-21 2011-10-27 Chiesi Farmaceutici S.P.A. "process for providing particles with reduced electrostatic charges"
US9228785B2 (en) 2010-05-04 2016-01-05 Alexander Poltorak Fractal heat transfer device
JP2012188677A (ja) * 2011-03-08 2012-10-04 Fujimi Inc 溶射用粉末
WO2012138529A1 (en) * 2011-04-06 2012-10-11 Dow Global Technologies Llc Novel polysaccharide derivatives and dosage forms
US9751957B2 (en) 2012-02-15 2017-09-05 Cydex Pharmaceuticals, Inc. Manufacturing process for cyclodextrin derivatives
AU2013226073B2 (en) 2012-02-28 2016-05-05 Cydex Pharmaceuticals, Inc. Alkylated cyclodextrin compositions and processes for preparing and using the same
JP2015155379A (ja) * 2012-05-23 2015-08-27 杏林製薬株式会社 吸入粉末剤及びその製造方法
EP2909239A4 (en) 2012-10-22 2016-06-08 Cydex Pharmaceuticals Inc ALKYLATED CYCLODEXTRIN COMPOSITIONS AND METHODS OF PREPARATION AND USE THEREOF
CA2889446C (en) 2012-10-25 2021-05-11 The General Hospital Corporation Combination therapies for the treatment of alzheimer's disease and related disorders
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
EP2991634A1 (en) 2013-04-30 2016-03-09 Otitopic Inc. Dry powder formulations and methods of use
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
US20160235667A1 (en) * 2013-10-02 2016-08-18 Vectura Limited Method and apparatus for making compositions for pulmonary administration
EP3060205A4 (en) 2013-10-22 2017-06-28 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
CA2977083A1 (en) 2014-02-20 2015-08-27 Kambiz Yadidi Dry powder formulations for inhalation
JP6914188B2 (ja) 2014-08-22 2021-08-04 サイデックス・ファーマシューティカルズ・インコーポレイテッド 分画アルキル化シクロデキストリン組成物ならびにその調製方法および使用方法
CN108498913A (zh) * 2015-05-16 2018-09-07 苏州汉方医药有限公司 一种药物器械组合成的用于治疗糖尿病的药盒
GB2543417B (en) 2015-09-11 2017-10-18 Guise Andrew An oral particulate composition
EP3485215B1 (en) 2016-07-12 2023-06-07 Alexander Poltorak System and method for maintaining efficiency of a heat sink
WO2018045217A1 (en) 2016-08-31 2018-03-08 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
KR20210070232A (ko) 2017-07-20 2021-06-14 아즈테라피즈 인코포레이티드 크로몰린 나트륨 및 이부프로펜의 분말화된 제형
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
CN111163827A (zh) * 2017-11-27 2020-05-15 丽年控股有限公司 汽化器***
SG11202007366YA (en) * 2018-02-06 2020-08-28 Nisshin Foods Inc Potato starch and potato starch composition
EP3817739A4 (en) 2018-07-02 2022-04-13 The General Hospital Corporation SODIUM CROMOGLYCATE AND ?-LACTOSE POWDER FORMULATIONS
FI20205368A1 (en) * 2020-04-07 2021-10-08 Aalto Univ Foundation Sr FORMULATION
EP4192436A1 (en) * 2020-08-10 2023-06-14 Ziropa, Inc. Compositions and methods for topical delivery
CN117794397A (zh) * 2021-08-19 2024-03-29 菲利普莫里斯生产公司 由两种颗粒材料形成的呈固体单一体形式的气溶胶形成基质

Family Cites Families (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3426011A (en) 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
GB1571629A (en) * 1977-11-30 1980-07-16 Fisons Ltd Pharmaceutical compositions containing beclomethasone dipropionate
EP0163836B1 (de) 1984-04-07 1988-10-12 Bayer Ag Verfahren und Vorrichtung zur Herstellung von Granulaten
US4920214A (en) 1986-04-16 1990-04-24 American Maize-Products Company Process for producing modified cyclodextrins
US4738923A (en) 1986-05-20 1988-04-19 American Maize-Products Company Process for producing and separating cyclodextrins
JPH0688898B2 (ja) * 1986-10-31 1994-11-09 帝人株式会社 アスコルビン酸類を含有する経鼻投与用粉末状組成物
JP2505430B2 (ja) * 1986-11-04 1996-06-12 帝人株式会社 塩基性アミノ酸を含有する経鼻投与用粉末状組成物
US5690954A (en) 1987-05-22 1997-11-25 Danbiosyst Uk Limited Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5658894A (en) 1989-04-23 1997-08-19 The Trustees Of The University Of Pennsylvania Compositions for inhibiting restenosis
US5760015A (en) 1988-01-19 1998-06-02 The Trustees Of The University Of Pennsylvania Cyclodextrin compounds and methods of making and use thereof
DK0392608T3 (da) 1989-04-12 1995-11-20 Procter & Gamble Faste konsumentproduktsammensætninger, der indeholder cyclodextrinkomplekser af lille partikelstørrelse
GB8920135D0 (en) * 1989-09-06 1989-10-18 Erba Carlo Spa Use of dehydrated cyclodextrins for improving drug dissolution
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9001635D0 (en) 1990-01-24 1990-03-21 Ganderton David Aerosol carriers
EP0710673A3 (en) 1990-05-21 1996-08-07 Toppan Printing Co Ltd Derivatives of cyclodextrins
GB9021433D0 (en) 1990-10-02 1990-11-14 Atomic Energy Authority Uk Power inhaler
ATE113202T1 (de) 1990-11-29 1994-11-15 Wei Ming Pharmaceutical Mfg Co Hilfsträger für direkte verpressung.
US5469843A (en) 1991-11-12 1995-11-28 Minnesota Mining And Manufacturing Company Inhalation device
DE4140689B4 (de) 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalationspulver und Verfahren zu ihrer Herstellung
US6673335B1 (en) 1992-07-08 2004-01-06 Nektar Therapeutics Compositions and methods for the pulmonary delivery of aerosolized medicaments
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5977070A (en) 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
US5324718A (en) 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
US5472954A (en) 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
US5284133A (en) * 1992-07-23 1994-02-08 Armstrong Pharmaceuticals, Inc. Inhalation device with a dose-timer, an actuator mechanism, and patient compliance monitoring means
US5525623A (en) 1993-03-12 1996-06-11 Arris Pharmaceutical Corporation Compositions and methods for the treatment of immunomediated inflammatory disorders
DK0689438T3 (da) 1993-03-26 2003-09-29 Franciscus Wilhelmus He Merkus Farmaceutiske præparater til intranasal administration af apomorfin
BE1007402A5 (nl) 1993-03-26 1995-06-06 Adir Nasale farmaceutische preparaten met progestagene stof.
DE69413528T2 (de) 1993-04-06 1999-05-06 Minnesota Mining & Mfg Vorrichtung zum deagglomerieren für trockenpulverinhalatoren
US5393880A (en) 1993-06-17 1995-02-28 American Maize-Products Company Cyclodextrin refining process
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
IS1796B (is) 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
GB9314614D0 (en) 1993-07-14 1993-08-25 Minnesota Mining & Mfg Dry powder inhalers
IL111184A (en) 1993-10-08 2000-08-13 Farmarc Nederland B V Of Cito Crystalline inclusion complex of diclofenac with unsubstituted beta-cyclodextrin
GB9322014D0 (en) 1993-10-26 1993-12-15 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
TW385308B (en) 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
ES2245780T3 (es) 1994-05-18 2006-01-16 Nektar Therapeutics Metodos y composiciones para la formulacion de interferones como un polvo seco.
EP0806945B1 (en) 1994-12-22 2003-04-23 AstraZeneca AB Therapeutic preparation for inhalation containing parathyro d hormone, pth
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US5569756A (en) 1995-03-21 1996-10-29 American Maize-Products Company Purification of chemically modified cyclodextrins
US6309671B1 (en) 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
US6258341B1 (en) 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
DK0828495T3 (da) 1995-06-01 2003-02-24 Searle & Co Misoprostolholdige faste stabiliserede dispersioner
US5576645A (en) * 1995-06-05 1996-11-19 Hughes Aircraft Company Sample and hold flip-flop for CMOS logic
US5677280A (en) 1995-06-07 1997-10-14 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
US5683983A (en) 1995-06-07 1997-11-04 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
US5654276A (en) 1995-06-07 1997-08-05 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US5668110A (en) 1995-06-07 1997-09-16 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
FR2735136B1 (fr) 1995-06-08 1997-08-14 Roquette Freres Composition pulverulente d'hydroxypropyl-betacyclodextrine et son procede de preparation.
GB9513218D0 (en) 1995-06-29 1995-09-06 Fisons Plc Inhalation device and method
BE1009856A5 (fr) 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
US6209538B1 (en) 1995-08-02 2001-04-03 Robert A. Casper Dry powder medicament inhalator having an inhalation-activated flow diverting means for triggering delivery of medicament
US5988163A (en) 1995-08-02 1999-11-23 Innovative Devices Dry powder medicament inhalator having an inhalation-activated flow diverting means for triggering delivery of delivery of medicament
US6022737A (en) 1995-11-02 2000-02-08 Amgen Inc. Formulations for non-viral in vivo transfection in the lungs
US5824668A (en) 1996-11-07 1998-10-20 Supergen, Inc. Formulation for administration of steroid compounds
US5935941A (en) 1997-10-24 1999-08-10 Pitha; Josef Alkylations of cyclodextrins leading to derivatives which have a ridgidly extended cavity
US5875776A (en) 1996-04-09 1999-03-02 Vivorx Pharmaceuticals, Inc. Dry powder inhaler
US5750549A (en) 1996-10-15 1998-05-12 Merck & Co., Inc. Cycloalkyl tachykinin receptor antagonists
GB9625843D0 (en) 1996-12-12 1997-01-29 Merck & Co Inc Phenyl spiroethercycloalkyl tachykinn receptor antagonists
US5929094A (en) 1996-10-25 1999-07-27 Merck & Co., Inc. Heteroaryl spiroethercycloalkyl tachykinin receptor antagonists
US5874418A (en) 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6046177A (en) 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
DK0889056T3 (da) 1997-07-01 2006-07-17 Pfizer Prod Inc Process for making a cyclodextrin
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6003512A (en) 1997-11-13 1999-12-21 Lovelace Respiratory Research Institute Dust gun-aerosol generator and generation
US6077871A (en) 1997-11-26 2000-06-20 Pfizer Inc. Droloxifene pharmaceutical compositions
JP4266399B2 (ja) 1997-12-04 2009-05-20 帝人株式会社 粉末状吸入用医薬品組成物
EP1075278A1 (en) 1998-01-13 2001-02-14 AstraZeneca UK Limited PHARMACEUTICAL COMPOSITIONS COMPRISING A COMPOUND HAVING DOPAMINE (D 2?) RECEPTOR AGONIST ACTIVITY AND A COMPOUND (B) HAVING $g(b) 2?-ADRENORECEPTOR AGONIST ACTIVITY
CA2320772A1 (en) 1998-02-23 1999-08-26 Cyclops, Ehf. High-energy cyclodextrin complexes
EP1102579B1 (de) * 1998-08-04 2003-03-19 Jago Research Ag Medizinische aerosolformulierungen
MA25590A1 (fr) 1998-09-14 2002-12-31 Inhale Therapeutic Syst Agent actif de delivraison de poudre seche
ES2192866T3 (es) 1998-11-13 2003-10-16 Jago Res Ag Polvo seco para inhalacion.
AU2879100A (en) 1999-02-12 2000-08-29 Miles A. Libbey Iii Formulation and system for intra-oral delivery of pharmaceutical agents
US6136603A (en) 1999-03-26 2000-10-24 Isis Pharmaceuticals Inc. Antisense modulation of interleukin-5 signal transduction
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
AU763039B2 (en) 1999-04-08 2003-07-10 Genentech Inc. Composition based on oppositely-charged polypeptides
JP2002543165A (ja) 1999-05-03 2002-12-17 バテル・メモリアル・インスティテュート エーロゾル化および吸入のための組成物
US6485706B1 (en) 1999-06-04 2002-11-26 Delrx Pharmaceutical Corp. Formulations comprising dehydrated particles of pharma-ceutical agents and process for preparing the same
US20030059376A1 (en) 1999-06-04 2003-03-27 Libbey Miles A. Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
US6858199B1 (en) * 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
ITMI991582A1 (it) 1999-07-16 2001-01-16 Chiesi Farma Spa Polveri costituite da particelle aventi la superficie perfettamente levigata da utilizzare come veicoli per la preparazione di miscele inala
ATE313318T1 (de) 1999-10-29 2006-01-15 Nektar Therapeutics Trockenpulverzusammensetzungen mit verbesserter dispersität
TWI242015B (en) 1999-11-29 2005-10-21 Akzo Nobel Nv 6-mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block
DE19961333B4 (de) * 1999-12-17 2006-12-14 Henkel Kgaa Verfahren zur Herstellung von Zuckertensidgranulaten
JP4057214B2 (ja) * 2000-03-06 2008-03-05 富士通株式会社 分布型光増幅装置および該方法ならびに光通信システム
GB0009469D0 (en) 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0011807D0 (en) 2000-05-16 2000-07-05 Quadrant Holdings Cambridge Formulation for inhalation
FR2812209B1 (fr) 2000-07-28 2003-02-07 Salomon Sa Planche d'un engin de glisse et engin de glisse comprenant une telle planche
CN100400031C (zh) 2000-11-29 2008-07-09 伊藤火腿株式会社 粉末制剂及其制备方法
JP4125512B2 (ja) * 2000-11-29 2008-07-30 伊藤ハム株式会社 粉末製剤及びその製造方法
WO2002056883A1 (en) 2001-01-18 2002-07-25 Wockhardt Limited Preparation of micron-size felodipine particles by microfluidization
AUPR272901A0 (en) 2001-01-25 2001-02-22 Gainful Plan Limited Method of preparing biological materials and preparations produced using same
FR2821844B1 (fr) 2001-03-08 2003-05-23 Roquette Freres Procede de preparation d'une beta-cyclodextrine directement compressible, et beta-cyclodextrine directement compressible ainsi obtenue
WO2002074200A1 (en) 2001-03-20 2002-09-26 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
US7034013B2 (en) 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
US20030028014A1 (en) 2001-04-26 2003-02-06 Chris Sikorski Agglomerated modified cyclodextrin and process for making same
US20030138403A1 (en) 2001-06-29 2003-07-24 Maxygen Aps Interferon formulations
DK1455755T3 (da) * 2001-11-20 2013-07-15 Civitas Therapeutics Inc Forbedrede partikelsammensætning til levering i lunge
KR20030044347A (ko) * 2001-11-29 2003-06-09 (주)에어스페이스 다기능 공기 청정기
AU2002351756A1 (en) 2001-12-21 2003-07-15 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
BR0215218A (pt) 2001-12-21 2004-11-16 Novo Nordisk As Composição aquosa lìquida, método para a preparação da mesma, uso de uma composição, e, métodos para a inibição da coagulação do sangue em um indivìduo, e inibição de reações mediadas pelo fator de tecido em um indivìduo
DE10205087A1 (de) 2002-02-07 2003-08-21 Pharmatech Gmbh Cyclodextrine als Suspensionsstabilisatoren in druckverflüssigten Treibmitteln
CA2478974C (en) 2002-03-20 2014-12-16 Advanced Inhalation Research, Inc. Inhalable sustained therapeutic formulations
US6869939B2 (en) 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
GB0219513D0 (en) 2002-08-21 2002-10-02 Norton Healthcare Ltd Inhalation compositions including coarse carrier
DE10240698A1 (de) 2002-09-04 2004-03-18 Symrise Gmbh & Co. Kg Cyclodextrinpartikel
US20040128654A1 (en) 2002-12-30 2004-07-01 Dichter Carl R. Method and apparatus for measuring variation in thread wait time
EP1709975A1 (en) 2003-07-10 2006-10-11 Kyowa Hakko Kogyo Co., Ltd. Tablet and process for producing the same
WO2005023308A1 (en) 2003-09-05 2005-03-17 Maxygen Holdings Ltd. Formulations of vitamin k-dependent polypeptides and sulfoalkyl ether cycloextrins
WO2005042584A2 (en) 2003-10-31 2005-05-12 The University Of Kansas Sulfoalkyl ether-alkyl ether cyclodextrin derivatives
AU2004311478A1 (en) 2003-12-31 2005-07-21 Cydex Pharmaceuticals, Inc. Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
CA2554927A1 (en) * 2004-02-03 2005-08-18 Chemagis Ltd. Stable amorphous forms of montelukast sodium
HUE042304T2 (hu) 2004-04-23 2019-06-28 Cydex Pharmaceuticals Inc DPI készítmény, amely szulfoalkil-éter-ciklodextrint tartalmaz
ATE464883T1 (de) 2004-07-22 2010-05-15 Bend Res Inc Geschmacksabdeckende formulierung mit einer retardierten wirkstoffformulierung und/oder schnell löslichem cyclodextrin
US20060128654A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
US20060194762A1 (en) 2004-12-23 2006-08-31 Olaf Reer Composition comprising an epothilone and methods for producing a composition comprising an epothilone
DE602005027415D1 (de) 2005-10-26 2011-05-19 Cydex Pharmaceuticals Inc Sulfoalkylether-cyclodextrin-zusammensetzungen und herstellungsverfahren dafür
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions

Also Published As

Publication number Publication date
DK3520779T3 (da) 2022-03-21
CN101098678A (zh) 2008-01-02
PL2708225T3 (pl) 2019-07-31
ES2717248T3 (es) 2019-06-20
JP2013028645A (ja) 2013-02-07
EP1755551A4 (en) 2010-04-21
EP3520779B1 (en) 2021-12-22
IL178728A0 (en) 2007-05-15
AU2010202503A1 (en) 2010-07-08
LT2708225T (lt) 2019-04-10
US20130197105A1 (en) 2013-08-01
US20200276314A1 (en) 2020-09-03
US10668160B2 (en) 2020-06-02
RU2006141358A (ru) 2008-05-27
HUE058227T2 (hu) 2022-07-28
KR20070002091A (ko) 2007-01-04
US20070175472A1 (en) 2007-08-02
US10117940B2 (en) 2018-11-06
KR20160008658A (ko) 2016-01-22
JP2017122114A (ja) 2017-07-13
PT3520779T (pt) 2022-03-22
KR101781166B1 (ko) 2017-09-22
HUE042304T2 (hu) 2019-06-28
EP2708225B1 (en) 2018-12-26
PT2708225T (pt) 2019-05-21
EP2708225A1 (en) 2014-03-19
WO2005104712A3 (en) 2007-06-07
CA2562585A1 (en) 2005-11-10
KR20120089705A (ko) 2012-08-13
JP6141906B2 (ja) 2017-06-07
US20120164184A1 (en) 2012-06-28
US11464862B2 (en) 2022-10-11
ES2909080T3 (es) 2022-05-05
JP2007534693A (ja) 2007-11-29
EP1755551A2 (en) 2007-02-28
KR101725225B1 (ko) 2017-04-12
AU2005237523A1 (en) 2005-11-10
DK2708225T3 (en) 2019-04-08
AU2010202503B2 (en) 2012-12-13
JP6538739B2 (ja) 2019-07-03
US8114438B2 (en) 2012-02-14
JP2015163634A (ja) 2015-09-10
SI2708225T1 (sl) 2019-05-31
MXPA06012240A (es) 2007-01-31
WO2005104712A2 (en) 2005-11-10
EP3520779A1 (en) 2019-08-07

Similar Documents

Publication Publication Date Title
BRPI0510119A (pt) formulação para dpi contendo sulfoaquil éter de ciclodextrina
Kermanizadeh et al. Nanomaterial translocation–the biokinetics, tissue accumulation, toxicity and fate of materials in secondary organs–a review
JP5372306B2 (ja) 多孔性微粒子および使用方法
Pourshahab et al. Preparation and characterization of spray dried inhalable powders containing chitosan nanoparticles for pulmonary delivery of isoniazid
Jiao et al. Influence of intranasal drugs on human nasal mucociliary clearance and ciliary beat frequency
CA2427282A1 (en) Mixtures or organic compounds for the treatment of airway diseases
WO2008005802A2 (en) Nasal formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
Parikh et al. Preparation and characterization of controlled release poly-ɛ-caprolactone microparticles of isoniazid for drug delivery through pulmonary route
WO2007070851A3 (en) Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
BRPI0707641A2 (pt) antibiàticos nebulizados para terapia de inalaÇço
JO3102B1 (ar) صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
BR0303348A (pt) Formulações de aerossol para administração pulmonar de medicamentos com o intuito de produzir efeito sistêmico
WO2008005692A2 (en) INHALANT FORMULATION CONTAINING SULFOALKYL ETHER γ-CYCLODEXTRIN AND CORTICOSTEROID
Buttini et al. Dose administration maneuvers and patient care in tobramycin dry powder inhalation therapy
Wang et al. Isoxyl aerosols for tuberculosis treatment: preparation and characterization of particles
Kawashima et al. Design of inhalation dry powder of pranlukast hydrate to improve dispersibility by the surface modification with light anhydrous silicic acid (AEROSIL 200)
Khan et al. Proliposome powder or tablets for generating inhalable liposomes using a medical nebulizer
FI3295943T3 (fi) Vesipitoinen suspensioaine, joka käsittää glukokortikosteroidinanopartikkeleita
Heng et al. Novel alternatives to reduce powder retention in the dry powder inhaler during aerosolization
Barazesh et al. Effect of pH and leucine concentration on aerosolization properties of carrier-free formulations of levofloxacin
de Castro et al. Development of inhaled formulation of modified clofazimine as an alternative to treatment of tuberculosis
US20130251790A1 (en) Low Dose Pharmaceutical Composition Comprising Zanamivir
IT201800006909A1 (it) Polvere secca di ambroxolo per uso inalatorio con target bronchiale
AU2014226192A8 (en) Dry pharmaceutical compositions comprising active agent nanoparticles bound to carrier particles
AU2013201437B2 (en) DPI formulation containing sulfoalkyl ether cyclodextrin

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: CYDEX PHARMACEUTICALS, INC. (US)

Free format text: NOME ALTERADO DE : CYDEX , INC.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL